Detalhe da pesquisa
1.
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Eur Heart J
; 40(44): 3593-3602, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31461239
2.
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Circulation
; 138(15): 1537-1550, 2018 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29941478
3.
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Diabetes Obes Metab
; 19(3): 387-393, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28120497
4.
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
J Am Heart Assoc
; 13(8): e032782, 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38563380
5.
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.
JACC Heart Fail
; 8(5): 359-368, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171760
6.
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
JAMA Cardiol
; 4(6): 515-523, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31017637
7.
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Lancet Diabetes Endocrinol
; 6(9): 691-704, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29937267
8.
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis.
J Clin Endocrinol Metab
; 95(6): 2596-606, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20392867